Kyongbo Pharmaceutical (214390) Fundamentals 2026 — P/E 469.4x, Revenue Analysis | SniperIQ
Kyongbo Pharmaceutical (214390) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩119.3B, trading at ₩4990.00 on the KSC. This SniperIQ fundamentals page covers Kyongbo Pharmaceutical's valuation (P/E 469.4x, P/B 0.8x), profitability (net margin 0.1%), revenue (₩264.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kyongbo Pharmaceutical's market cap?
Kyongbo Pharmaceutical (214390) has a market capitalization of approximately ₩119.3B, trading at ₩4990.00 on the KSC. Market cap moves with the live share price.
What is Kyongbo Pharmaceutical's P/E ratio?
Kyongbo Pharmaceutical's trailing twelve-month P/E ratio is 469.4x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kyongbo Pharmaceutical?
Kyongbo Pharmaceutical runs a net profit margin of 0.1%, a gross margin of 38.5%, and an operating margin of 1.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kyongbo Pharmaceutical generate?
Kyongbo Pharmaceutical reported revenue of ₩264.1B for fiscal year 2025, with net income of ₩182M and earnings per share (EPS) of 7.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kyongbo Pharmaceutical pay a dividend?
Kyongbo Pharmaceutical offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kyongbo Pharmaceutical financially healthy?
Kyongbo Pharmaceutical carries a debt-to-equity ratio of 0.99x and a current ratio of 0.94x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kyongbo Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kyongbo Pharmaceutical (214390) the key facts are: market cap ₩119.3B, P/E 469.4x, revenue ₩264.1B, 52-week range 4800-9300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kyongbo Pharmaceutical's full fundamentals live
Get Kyongbo Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.